Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01049334 · ClinicalTrials.gov registry record · Phase 3

A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis

A Phase 3 study, sponsored by Reckitt Benckiser.

Completed
Registry status
Phase 3
Development phase
204
Enrollment target

NCT01049334 is a Phase 3 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 204 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01049334, a Phase 3 study, has completed, sponsored by Reckitt Benckiser.

COMPLETED
Registry status
Phase 3
Development phase
204 participants
Enrollment target

Study Summary

The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.

Interventions

  • DRUG Placebo
  • DRUG Flurbiprofen

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2009-11
Est. Completion 2011-03
Phase Phase 3

Sponsor

Reckitt Benckiser

8 total trials

What the Registry Record Tells You About NCT01049334

The ClinicalTrials.gov registry entry for NCT01049334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01049334 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01049334 about?

NCT01049334 is a clinical study titled "A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis". The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.

What is the current status of trial NCT01049334?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2009-11. Estimated completion is 2011-03.

What interventions are being tested in trial NCT01049334?

The interventions under investigation include: Placebo (DRUG), Flurbiprofen (DRUG).

Who is sponsoring clinical trial NCT01049334?

This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.